Evidence mapPaperPMID 41323638Full record

ArticleBone reports2025

Increased fatty acid availability improves the osteo-anabolic effects of intermittent parathyroid hormone (iPTH) in murine models.

Santosh Thapa, Jake Newberry, S V V S Ravi Mangu, Ron C M Helderman, Ananya Nandy, Cameron Fawcett, Sasidhar Uppuganti, Jeffry S Nyman, Elizabeth Rendina-Ruedy

Abstract read
In one paragraph

Article in Bone reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Santosh ThapaDepartment of Medicine, Division of Clinical Pharmacology, Vanderbilt University Medical Center, Nashville, TN, 37232, USA.
Jake NewberryDepartment of Medicine, Division of Clinical Pharmacology, Vanderbilt University Medical Center, Nashville, TN, 37232, USA.
S V V S Ravi ManguDepartment of Medicine, Division of Clinical Pharmacology, Vanderbilt University Medical Center, Nashville, TN, 37232, USA.
Ron C M HeldermanDepartment of Medicine, Division of Clinical Pharmacology, Vanderbilt University Medical Center, Nashville, TN, 37232, USA.
Ananya NandyDepartment of Medicine, Division of Clinical Pharmacology, Vanderbilt University Medical Center, Nashville, TN, 37232, USA.
Cameron FawcettDepartment of Medicine, Division of Clinical Pharmacology, Vanderbilt University Medical Center, Nashville, TN, 37232, USA.
Sasidhar UppugantiDepartment of Orthopaedic Surgery, Vanderbilt University Medical Center, 1215 21st Ave. S, Suite 4200, Nashville, TN, 37232, USA.
Jeffry S NymanDepartment of Orthopaedic Surgery, Vanderbilt University Medical Center, 1215 21st Ave. S, Suite 4200, Nashville, TN, 37232, USA.
Elizabeth Rendina-RuedyDepartment of Medicine, Division of Clinical Pharmacology, Vanderbilt University Medical Center, Nashville, TN, 37232, USA.

Funding

Parathyroid hormone (PTH) modulates lipid metabolism in the skeletal nicheR01AG069795 · VANDERBILT UNIVERSITY MEDICAL CENTER · 2025 to 2025
$123k
BLRD VA IK6 BX007117NIAMS NIH HHS R21 AR080387NIA NIH HHS R01 AG069795
6 · The paper itself

Abstract

Osteoporosis is a major public health problem which results in reduced bone mineral density (BMD) and increased fracture risk. Osteoporosis-related fractures often lead to multiple comorbidities which can significantly reduce longevity and diminish one's quality of life. While anabolic agents that increase bone formation, such as parathyroid hormone (PTH), have aided in the management of osteoporosis, patients still experience adverse side-effects along with variations in therapeutic response. Therefore, continued development of refined therapeutic interventions as well as improving efficacy is necessary. Relative to this, the current experiments report on the ability to harness PTH's impact to modulate osteoblast bioenergetic capacity to promote bone formation by supplying fatty acid substrates to meet this energetic demand. To accomplish this, mice were fed a moderately 'high' fat diet (2.5×) or control fat, as to not induce metabolic perturbations, while treating with or without PTH for 4 weeks. This dietary regimen resulted in improved bone parameters in mice fed the high fat diet compared to control diet. To directly test the contribution of increased exogenous fatty acid substrates during PTH treatment, we next introduced oleic acid simultaneous to PTH treatment for 4 weeks, and again showed improved skeletal parameters compared to the vehicle-control treated mice. These data support previous publications that demonstrate the osteoanabolic responsiveness of osteoblasts to PTH requires fatty acid substrates. These data further expand on these findings, by providing evidence that PTH efficacy can be improved by supplying exogenous fatty acid substrates, either by dietary or direct interventions.

Indexed as

BoneDietMetabolismOsteoporosisTeriparatide

Identifiers

PMID41323638
PMCPMC12661984

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.